Global Urea Cycle Disorders Treatment Market Landscape to 2027: Increasing Prevalence and Substantial R&D Efforts
Company Logo
Company Logo

Dublin, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Urea Cycle Disorders Treatment Market 2017-2027" report has been added to ResearchAndMarkets.com's offering.

The global urea cycle disorders treatment market is poised for impressive growth in the forecast period from 2023 to 2027. This upward trajectory is fueled by a combination of factors, including the increasing prevalence of urea cycle disorders and substantial research and development efforts.

Various catalysts are propelling this market's expansion, including heightened investments in research and development, growing initiatives by key industry players, heightened awareness, improved healthcare services, and a surge in innovative diagnostic methods.

Rising Prevalence of Urea Cycle Disorders

A surge in the prevalence of urea cycle disorders is expected to drive global market growth. Reports from the Centers for Disease Control and Prevention (CDC) indicate a projected incidence of 1 in 8500 births for urea cycle disorders. However, the actual number may be higher due to undiagnosed cases.

It is estimated that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be attributed to undiagnosed inborn metabolic errors such as urea cycle disorders. This underscores the urgency of addressing and treating these disorders, thus catalyzing growth in the urea cycle disorders treatment market.

Initiatives and Awareness Fueling Growth

Governments and private organizations worldwide have ramped up efforts to support market growth. These initiatives encompass substantial investments in research and development, increased awareness campaigns, extensive research endeavors, clinical trials, and streamlined regulatory approvals.

For instance, the merger of Mead Johnson Nutrition Company (MJN) with Reckitt Benckiser Group plc (RB) in 2017 bolstered the dietary management of urea cycle disorders by integrating brands like Enfa and Nutramigen into RB's consumer health portfolio. Similarly, Horizon Pharma plc's UCD in Common initiative offers resources and support for individuals with urea cycle disorders and their families.

Leading Players and Geographic Outlook

Market players shaping the global urea cycle disorders treatment market landscape include:

  • Bausch Health Companies Inc.

  • Recordati Rare Diseases

  • Eurocept Pharmaceuticals Holding (Lucane Pharma SA)

  • Acer Therapeutics

  • Ultragenyx Pharmaceutical

  • Aeglea BioTherapeutics

  • Arcturus Therapeutics, Inc.

  • Orpharma Pty. Ltd.

  • Selecta Biosciences, Inc

  • Abbott Laboratories, Inc.

In terms of geographic spread, the United States is anticipated to be a pivotal market due to its escalating cases of urea cycle disorders.